Outcomes in patients (pts) with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) treated with systemic therapy from real world experience (ORCHID) study.

被引：0
|
作者：
Damaj, Gandhi Laurent
Hampp, Christian
Bachy, Emmanuel
Prochazka, Katharina
Jo, Jae-Cheol
Kim, Tae Min
Oberic, Lucie
Townsend, William
Jalbert, Jessica J.
Ma, Qiufei
Kamat, Siddhesh
Wang, Joy
Ambati, Srikanth R.
Mohamed, Hesham
Chaudhry, Aafia
Thorley, Eileen
Rippin, Gerd
Harnett, James
Thieblemont, Catherine
机构：
[1] Univ Hosp Sch Med, Hematol Clin, Inst Hematol, Caen, France
[2] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[3] Hosp Civils Lyon, Dept Hematol, Lyon, France
[4] Univ Claude Bernard Lyon 1, Lyon, France
[5] Med Univ Graz, Univ Clin Internal Med, Dept Clin Hematol, Graz, Austria
[6] Univ Ulsan, Coll Med, Dept Hematol & Oncol, Ulsan Univ Hosp, Ulsan, South Korea
[7] Seoul Natl Univ Hosp, Seoul, South Korea
[8] Inst Univ Canc, Dept Hematol, Toulouse, France
[9] Univ Coll London Hosp, Canc Res UK, London, England
[10] Univ Coll London Hosp, UCL Canc Trials Ctr, London, England
[11] IQVIA Inc, Durham, NC USA
[12] IQVIA, Frankfurt, Germany
[13] Univ Paris Cite, Paris, France
[14] Hop St Louis, AP HP, Hematooncol, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19067
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Real-World Use of Tafasitamab (tafa) for Relapsed or Refractory (R/R) Diffuse Large B- Cell Lymphoma (DLBCL) Among Racial and Ethnic Minorities in the United States
    Epperla, Narendranath
    Nastoupil, Loretta J.
    Savill, Kristin M. Zimmerman
    Feinberg, Bruce
    Galvin, John
    Pathak, Prathamesh
    Gordon, Sarah
    Amoloja, Theresa
    Llorente, Mae
    Saverno, Kimberly
    [J]. BLOOD, 2023, 142
  • [42] A Phase Ib Open-Label Study of MRG001 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
    Zhu, Jun
    Song, Yuqin
    Guo, Ye
    Zhou, Keshu
    Li, Wenyu
    Yang, Yu
    Cai, Qingqing
    Wang, Zhao
    Yang, Haiyan
    [J]. BLOOD, 2023, 142
  • [43] Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Ayyappan, Sabarish
    Kim, Won Seog
    Kim, Tae Min
    Walewski, Jan
    Cho, Seok-Goo
    Jarque, Isidro
    Iskierka-Jazdzewska, Elzbieta
    Poon, Michelle
    Oh, Sung Yong
    Lim, Francesca Lorraine Wei Inng
    Carpio, Cecilia
    Tan, Tran-Der
    Gutierrez, Antonio
    Zhang, Huilai
    Cao, Junning
    Zhang, Mingzhi
    Tessoulin, Benoit
    Li, Jingjin
    Ufkin, Melanie
    Shariff, Saleem
    Chi, Lei
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth
    Prince, H. Miles
    [J]. BLOOD, 2023, 142
  • [44] Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy
    Argnani, Lisa
    Broccoli, Alessandro
    Pellegrini, Cinzia
    Fabbri, Alberto
    Puccini, Benedetta
    Bruna, Riccardo
    Tisi, Maria Chiara
    Masia, Francesco
    Flenghi, Leonardo
    Nizzoli, Maria Elena
    Musso, Maurizio
    Salerno, Marilena
    Scalzulli, Potito Rosario
    Dessi', Daniela
    Ferrarini, Isacco
    Pennese, Elsa
    Lucchini, Elisa
    Rossi, Francesca Gaia
    Minoia, Carla
    Gherlinzoni, Filippo
    Musto, Pellegrino
    Patti, Caterina
    Stefoni, Vittorio
    Zinzani, Pier Luigi
    [J]. HEMASPHERE, 2022, 6 (12): : E798
  • [45] Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.
    Ozcan, Muhit
    Lee, Seung Tae
    Mensah, Felix
    Modi, Dipenkumar
    Fossa, Alexander
    Kim, Won Seog
    Paszkiewicz-Kozik, Ewa
    Sawalha, Yazeed
    Sevindik, Omur Gokmen
    Norasetthada, Lalita
    Santoro, Armando
    Pathiraja, Kumudu
    Chakraborty, Samhita
    Marinello, Patricia
    Lavie, David
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study.
    Jaeger, Ulrich
    Worel, Nina
    McGuirk, Joseph
    Riedell, Peter A.
    Fleury, Isabelle
    Borchmann, Peter
    Du, Yan
    Abdelhady, Ahmed M.
    Han, Xia
    Martinez-Prieto, Marcela
    Waller, Edmund K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] Radiotherapy Combined Chimeric Antigen Receptor T-Cells Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma(R/R DLBCL)
    Zhou, Lili
    Liu, Yifan
    Ye, Shiguang
    Li, Ping
    Li, Shaoguang
    Liang, Aibin
    [J]. BLOOD, 2023, 142
  • [48] Challenges in Administering Salvage Therapy and Outcomes of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A LMIC Real-World Study
    Charanpreet Singh
    Aditya Jandial
    Arihant Jain
    Deepesh Lad
    Alka Khadwal
    Rajender Basher
    Amanjit Bal
    Pankaj Malhotra
    Gaurav Prakash
    [J]. Indian Journal of Hematology and Blood Transfusion, 2024, 40 : 231 - 236
  • [49] Challenges in Administering Salvage Therapy and Outcomes of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A LMIC Real-World Study
    Singh, Charanpreet
    Jandial, Aditya
    Jain, Arihant
    Lad, Deepesh
    Khadwal, Alka
    Basher, Rajender
    Bal, Amanjit
    Malhotra, Pankaj
    Prakash, Gaurav
    [J]. INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2024, 40 (02) : 231 - 236
  • [50] Open-label phase 2 study of bispecific T-cell engager (BiTE®) antibody blinatumomab in patients (pts) with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
    Viardot, A.
    Goebeler, M.
    Pfreundschuh, M.
    Adrian, N.
    Libicher, M.
    Hess, G.
    Zettl, F.
    Neumann, S.
    Degenhard, E.
    Stieglmaier, J.
    Zhang, A.
    Nagorsen, D.
    Bargou, R. C.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 33 - 33
12345